Iovance Biotherapeutics falls 6% on Q2 top-line miss (NASDAQ:IOVA)

Iovance Biotherapeutics falls 6% on Q2 2022 bottom line miss
Quoted from Various Sources
Published for: Ipodifier
Beyond Business
Iovance Biotherapeutics falls 6% on Q2 2022 bottom line miss
Quoted from Various Sources
Published for: Ipodifier